Each month, The Clinical Advisor makes one new clinical feature available ahead of print. Don’t forget to take the poll. The results will be published in the next month’s issue. Healthcare providers ...
A single genetic test could potentially replace the current two-step approach to diagnosing rare developmental disorders in children. This shift could enable earlier diagnoses for families and save ...
It wasn’t all that long ago that we cracked the human genome, and in just a few short years we became used to direct-to-consumer genetic sequencing companies, like Ancestry.com and 23&Me, which could ...
A single genetic test could potentially replace the current two-step approach to diagnosing rare developmental disorders in children. This shift could enable earlier diagnoses for families and save ...
Clinicians should prioritize genetic testing for young children who show signs of intellectual disability (ID) or developmental delays, according to a new report from the American Academy of ...
In India, rare diseases are not so rare. It is estimated that around 70 million Indians live with one of more than 7,000 rare ...
Nucleus Genomics, the next-generation genetic testing and analysis company, today announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone. DNA and ...
Join us for an insightful webinar on the use of polygenic risk scores (PRS) for cardiovascular disease (CVD). The analysis of genetic variation across large populations plays a crucial role in ...
Nucleus Genomics, the next-generation genetic testing and analysis company, today announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone. DNA and ...
NEW YORK--(BUSINESS WIRE)--Nucleus Genomics, a next-generation consumer genetic testing and analysis company, has raised $14 million in a new funding round led by Alexis Ohanian's Seven Seven Six. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results